FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
1-Year Return
23.12%
This Quarter Return
+13.51%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$14.1B
AUM Growth
+$1.66B
(+13%)
Cap. Flow
+$700M
Cap. Flow
% of AUM
4.96%
Top 10 Holdings %
Top 10 Hldgs %
32.58%
Holding
150
New
30
Increased
52
Reduced
23
Closed
23
Top Buys
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$498M |
| 2 |
Boston Scientific
BSX
|
$316M |
| 3 |
Alphabet (Google) Class C
GOOG
|
$208M |
| 4 |
Hilton Worldwide
HLT
|
$132M |
| 5 |
New York Times
NYT
|
$127M |
Top Sells
| 1 |
IAC Inc
IAC
|
$456M |
| 2 |
WUBA
58.COM INC
WUBA
|
$268M |
| 3 |
Salesforce
CRM
|
$208M |
| 4 |
Qiagen
QGEN
|
$123M |
| 5 |
CZR
Caesars Entertainment Corporation
CZR
|
$97.2M |
Sector Composition
| 1 | Healthcare | 41.8% |
| 2 | Communication Services | 18.01% |
| 3 | Technology | 8.41% |
| 4 | Financials | 7.57% |
| 5 | Industrials | 5.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Blackstone
BX
$133B
| $200M | 1.38% |
3,829,336
+1,061,017
| +38% | +$55.4M |
|
27
Iovance Biotherapeutics
IOVA
$901M
| $196M | 1.36% |
5,955,000
-582,500
| -9% | -$19.2M |
|
28
Ascendis Pharma
ASND
$12.5B
| $193M | 1.33% |
1,250,000
+110,000
| +10% | +$17M |
|
29
Alibaba
BABA
$323B
| $180M | 1.25% |
612,585
-314,115
| -34% | -$92.3M |
|
30
General Dynamics
GD
$86.8B
| $177M | 1.22% |
1,277,107
+125,626
| +11% | +$17.4M |
|
|
31
Salesforce
CRM
$239B
| $176M | 1.21% |
698,315
-827,333
| -54% | -$208M |
|
32
Alnylam Pharmaceuticals
ALNY
$59.2B
| $175M | 1.21% |
1,200,000
+150,000
| +14% | +$21.8M |
|
|
MYOK
33
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $167M | 1.16% |
1,225,000
+350,000
| +40% | +$47.7M |
|
|
WMGI
34
DELISTED
Wright Medical Group Inc
WMGI
| $156M | 1.08% |
5,097,546
+997,546
| +24% | +$30.5M |
|
35
TransUnion
TRU
$17.5B
| $153M | 1.06% |
1,814,132
+621,385
| +52% | +$52.3M |
|
36
Equinix
EQIX
$75.7B
| $152M | 1.05% |
200,164
-67,433
| -25% | -$51.3M |
|
|
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $145M | 1.01% |
875,000
+225,000
| +35% | +$37.4M |
|
|
38
Hilton Worldwide
HLT
$64B
| $132M | 0.91% |
+1,545,877
| New | +$132M |
|
|
PLYA
39
DELISTED
Playa Hotels & Resorts
PLYA
| $128M | 0.89% |
30,606,930
| – | – |
|
40
Fate Therapeutics
FATE
$116M
| $125M | 0.86% |
3,125,000
-375,000
| -11% | -$15M |
|
41
Howmet Aerospace
HWM
$71.8B
| $121M | 0.83% |
7,210,388
+6,011,202
| +501% | +$101M |
|
|
LVGO
42
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $116M | 0.8% |
+830,000
| New | +$116M |
|
|
BMY.RT
43
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $99.2M | 0.69% |
44,073,000
-127,000
| -0.3% | -$286K |
|
44
Cigna
CI
$81.5B
| $85.1M | 0.59% |
502,231
+2,231
| +0.4% | +$378K |
|
45
Sarepta Therapeutics
SRPT
$1.96B
| $84.3M | 0.58% |
600,000
+75,000
| +14% | +$10.5M |
|
|
MXIM
46
DELISTED
Maxim Integrated Products
MXIM
| $83.2M | 0.58% |
+1,230,000
| New | +$83.2M |
|
47
Enanta Pharmaceuticals
ENTA
$189M
| $81.3M | 0.56% |
1,775,000
+25,000
| +1% | +$1.14M |
|
48
NovoCure
NVCR
$1.37B
| $80.7M | 0.56% |
+725,000
| New | +$80.7M |
|
49
FibroGen
FGEN
$48.9M
| $76.1M | 0.53% |
74,000
+9,000
| +14% | +$9.25M |
|
|
KSU
50
DELISTED
Kansas City Southern
KSU
| $71.2M | 0.49% |
+394,000
| New | +$71.2M |
|